Skip to main content
SpringerLink
Log in

IBD

Etrasimod for ulcerative colitis: evaluating phase III results

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

An Author Correction to this article was published on 03 July 2023

This article has been updated

Recent clinical trials have demonstrated efficacy and safety of etrasimod, a new sphingosine-1-phosphate receptor modulator, in the treatment of patients with moderately-to-severely active ulcerative colitis. Etrasimod is a promising new oral treatment option for ulcerative colitis, although long-term efficacy and safety data should be accumulated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

References

  1. Kirchgesner, J. et al. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009–2014. Aliment. Pharmacol. Ther. 45, 37–49 (2017).

    Article  CAS  PubMed  Google Scholar 

  2. Kobayashi, T. et al. Ulcerative colitis. Nat. Rev. Dis. Primers 6, 74 (2020).

    Article  PubMed  Google Scholar 

  3. Grossberg, L. B., Papamichael, K. & Cheifetz, A. S. Review article: emerging drug therapies in inflammatory bowel disease. Aliment. Pharmacol. Ther. https://doi.org/10.1111/apt.16785 (2022).

    Article  PubMed  Google Scholar 

  4. Sandborn, W. J. et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N. Engl. J. Med. 374, 1754–1762 (2016).

    Article  CAS  PubMed  Google Scholar 

  5. Sandborn, W. J. et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet https://doi.org/10.1016/s0140-6736(23)00061-2 (2023).

    Article  PubMed  Google Scholar 

  6. Lasa, J. S., Olivera, P. A., Danese, S. & Peyrin-Biroulet, L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol. Hepatol. 7, 161–170 (2022).

    Article  PubMed  Google Scholar 

  7. Buisson, A. et al. Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 study. Inflamm. Bowel Dis. https://doi.org/10.1093/ibd/izac119 (2023).

    Article  PubMed  Google Scholar 

  8. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316–326 (2022).

    Article  CAS  PubMed  Google Scholar 

  9. Matsuoka, K. et al. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open. J. Gastroenterol. Hepatol. https://doi.org/10.1111/jgh.15923 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan

    Katsuyoshi Matsuoka

  2. Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, Japan

    Toshifumi Hibi

Authors
  1. Katsuyoshi Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshifumi Hibi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshifumi Hibi.

Ethics declarations

Competing interests

T.H. has received lecture fees from AbbVie, EA Pharma, Janssen, JIMRO, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer, Sandoz, Takeda Pharmaceutical and Zeria, advisory/consultancy fees from AbbVie, Celltrion Healthcare, EA Pharma, Eli Lilly, Gilead Sciences, Janssen, Mitsubishi Tanabe Pharma, Nichi-Iko, Nippon Kayaku, Takeda Pharmaceutical and Zeria, and research grants from AbbVie, Activaid, Alfresa Pharma, Bristol-Myers Squibb, Ferring Pharmaceuticals, Eli Lilly, Gilead Sciences, JIMRO, JMDC Inc., Janssen, Kyorin Pharmaceutical, Miyarisan, Mochida Pharmaceutical, Nippon Kayaku and Pfizer. K.M. received research grants from AbbVie, EA Pharma, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Kyorin Pharmaceutical, Kissei Pharmaceutical, JIMRO and Nippon Kayaku, and payment or honoraria for lectures from AbbVie, EA Pharma, Mochida Pharmaceutical, Kyorin Pharmaceutical, Kissei Pharmaceutical, Janssen, JIMRO, Gilead Sciences, Pfizer, Takeda Pharmaceutical, Zeria, Miyarisan, Nippon Kayaku, Celltrion Healthcare, Eli Lilly and Mitsubishi Tanabe Pharma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matsuoka, K., Hibi, T. Etrasimod for ulcerative colitis: evaluating phase III results. Nat Rev Gastroenterol Hepatol 20, 762–763 (2023). https://doi.org/10.1038/s41575-023-00793-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-023-00793-0

  • Springer Nature Limited

Search

Navigation